RecruitingPhase 2/3

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

United States150 participantsStarted 2025-09-12

Plain-language summary

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included. Exclusion Criteria: History of or suspected CMV disease within 6 months prior is excluded.

What they're measuring

Occurrence of leukopenia

Timeframe: During the duration of CMV prophylaxis (6 months for moderate risk and 12 months for high risk from start of therapy)

Occurrence of neutropenia

Timeframe: During the duration of CMV prophylaxis (Up to 6 months for moderate risk and up to 12 months for high risk from start of therapy)

Trial details

NCT IDNCT07079735

SponsorColumbia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-01-17

Contact for this trial

Afsana Rahman, MD

2123054600 ar3262@cumc.columbia.edu

View on ClinicalTrials.gov More CMV Viremia trials